Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Jul;76(1):107-13.
doi: 10.1111/bcp.12055.

A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin

Xavier Delavenne  1 , Edouard Ollier, Thierry Basset, Laurent Bertoletti, Sandrine Accassat, Arnauld Garcin, Silvy Laporte, Paul Zufferey, Patrick Mismetti
Affiliations
Randomized Controlled Trial

A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin

Xavier Delavenne et al. Br J Clin Pharmacol. 2013 Jul.

Abstract

Aim: The aim of this study was to develop a PK/PD model to assess drug-drug interactions between dabigatran and P-gp modulators, using the example of clarithromycin, a strong inhibitor of P-gp.

Methods: Ten healthy male volunteers were randomized to receive in the first treatment period a single 300 mg dose of dabigatran etexilate (DE) and in the second treatment period 500 mg clarithromycin twice daily during 3 days and then 300 mg DE plus 500 mg clarithromycin on the fourth day, or the same treatments in the reverse sequence. Dabigatran plasma concentration and ecarin clotting time (ECT) were measured on 11 blood samples. Models were built using a non-linear mixed effect modelling approach.

Results: The best PK model was based on an inverse Gaussian absorption process with two compartments. The relationship between dabigatran concentration and ECT was implemented as a linear function. No continuous covariate was associated with a significant decrease in the objective function. The concomitant administration of clarithromycin induced a significant change only in DE bioavailability, which increased from 6.5% to 10.1% in the presence of clarithromycin. Clarithromycin increased peak concentration and AUC by 60.2% and 49.1% respectively.

Conclusion: The model proposed effectively describes the complex PK of dabigatran and takes into account drug-drug interactions with P-gp activity modulators, such as clarithromycin.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Absorption rate of dabigatran with and without clarithromycin. The solid black line represents the median absorption rate of dabigatran without clarithromycin (A) and with clarithromycin (B). The dashed lines indicate the 5% and 95% percentiles
Figure 2
Figure 2
Visual predictive check. The envelope indicates the 90% confidence interval of simulations. The grey circles represent data obtained without clarithromycin. The white circles represent data obtained with clarithromycin
Figure 3
Figure 3
Pharmacokinetic profiles of three volunteers. Fit of dabigatran plasma concentration with (solid line) and without (dashed line) clarithromycin. Grey circles represent data obtained without clarithromycin. White circles represent data obtained with clarithromycin
See this image and copyright information in PMC

References

    1. Eriksson BI, Dahl OE, Büller HR, Hettiarachchi R, Rosencher N, Bravo M-L, Ahnfelt L, Piovela F, Stangier J, Lebo KA, Reilly P. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005;3:103–111. - PubMed
    1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151. - PubMed
    1. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36:386–399. - PubMed
    1. Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stähle H, Rathgen K, Svärd R. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45:555–563. - PubMed
    1. CHMP. Pradaxa, INN- dabigatran etexilate CHMP assessment report for radaxa. EMEA, editor. 2008 Apr 10; 1–36. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_asses... (last accessed 30 September 2012)

Publication types

MeSH terms